首页> 外文期刊>BMC Neurology >Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke
【24h】

Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke

机译:仅在急性缺血性中风患者中小剂量阿司匹林加双嘧达莫与阿司匹林治疗的比较评价

获取原文
           

摘要

Background Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs. The aim of the present study was to evaluate the effect of this drug combination on acute and long-term prognosis of ischaemic stroke. Methods Patients without atrial fibrillation admitted to the stroke unit with acute ischaemic stroke (n = 554) or TIA (n = 108) were studied during acute hospital care and up to 12 months after discharge from hospital. Results Prior to acute stroke 62 patients were treated with A + D while 247 patients were treated with A only. No beneficial effects of the combination A + D compared to A only were noted on stroke severity and/or acute in-hospital mortality. However, survival analysis by Cox-proportional hazard model demonstrated lower 12-months all-cause mortality in patients discharged with A + D (n = 275) compared with patients on A only (HR, 0.52; CI, 0.32-0.86; p = 0.011; n = 262) after adjusting for age, baseline NIHSS, previous stroke, previous myocardial infarction and type 2 diabetes. We also noted a tendency towards lower all-cause mortality at 3 months with use of A + D, but this was not statistically significant (p = 0.12). Conclusions Pre-stroke treatment with a combination of low-dose A + D does not reduce the severity of acute stroke, nor does it reduce the acute in-hospital mortality. However, treatment with A + D at discharge from hospital is seemingly associated with lower long-term mortality compared with A only, contrary to the results from previous randomised studies. However, our results must be interpreted with extreme caution considering the non-randomised study design.
机译:背景先前的研究表明,小剂量阿司匹林(A)的中风前治疗可降低急性缺血性中风的严重程度,但对阿司匹林和双嘧达莫联合使用对中风前治疗的疗效知之甚少(A + D )和这些药物的中风后作用。本研究的目的是评估这种药物组合对缺血性中风的急性和长期预后的影响。方法对急性缺血性卒中(554例)或TIA(108例)的卒中单元中无房颤的患者进行了急性住院治疗和出院后长达12个月的研究。结果急性卒中前62例接受A + D治疗,而247例仅接受A +治疗。与仅使用A相比,没有发现A + D组合对卒中严重程度和/或急性住院死亡率的有益影响。但是,通过Cox比例风险模型进行的生存分析表明,与仅接受A疗法的患者相比,接受A + D疗法的患者(n = 275)的12个月全因死亡率较低(HR,0.52; CI,0.32-0.86; p = 0.011; n = 262)在调整了年龄,基线NIHSS,先前的中风,先前的心肌梗塞和2型糖尿病之后。我们还注意到使用A + D可以降低3个月全因死亡率的趋势,但这在统计学上并不显着(p = 0.12)。结论低剂量A + D联合中风治疗并不能降低急性中风的严重性,也不能降低急性住院死亡率。然而,与以前的随机研究结果相反,出院时用A + D治疗似乎与较低的长期死亡率相关。但是,考虑到非随机研究设计,必须非常谨慎地解释我们的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号